June 14, 2016June 14, 2016

Theravance Reports Positive Phase 1 Data on TD-1473, a JAK Inhibitor for IBD

Theravance Biopharma, Inc., recently reported positive data from its Phase 1 clinical trial assessing TD-1473, a new and oral pan-Janus kinase (JAK) inhibitor designed to enter the gastrointestinal tract and target inflammation without significant ... Read more

November 19, 2015November 19, 2015

Potential Approach to Decrease Immune Responses in IBD Suggested by BIDMC Researchers

News

In a new study entitled “NADH oxidase-dependent CD39 expression by CD8+ T cells modulates interferon gamma responses via generation of adenosine,” a team of researchers shed light on the role ... Read more